Oestrogen receptor-positive (ER+) breast cancer comprises approximately 75% of all breast cancers and treatments targeting oestrogen synthesis (aromatase inhibitors) or the ER (tamoxifen) are the most effective adjuvant therapies. Here, CYP19A1 is linked to breast cancer.